NDAORALTABLET
Approved
Jan 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
ALDACTAZIDE (spironolactone and hydrochlorothiazide) by Pfizer is aldosterone antagonists [moa]. Approved for thiazide diuretic [epc], hypertension, to lower blood pressure and 15 more indications. First approved in 1961.
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDACTAZIDE is an oral combination tablet containing spironolactone (aldosterone antagonist) and hydrochlorothiazide (thiazide diuretic) approved in 1961. It treats hypertension and heart failure by dual mechanism: blocking aldosterone to retain potassium while promoting sodium/water excretion via thiazide action. The fixed combination is particularly indicated for diuretic-induced hypokalemia in congestive heart failure patients.
$32KPart D
LOE ApproachingDeclining
This product is in late-stage lifecycle with minimal market presence and few commercial development opportunities; team size is likely skeleton-level maintenance rather than growth-focused.
Mechanism of Action
Aldosterone Antagonists
Pharmacologic Class:
Thiazide Diuretic
Indications (17)
Worked on ALDACTAZIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.